Septic ShockPhase 1/2CORVICTES-ΥΜNCT03649633
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
A Phase 1/2 study testing Stress-dose Hydrocortisone plus Vitamin C in people with Septic Shock, run by University of Athens at 1 site in Greece.
Trial summary
This study has been approved as a nested substudy of a multicenter trial (CORVICTES, Clinicaltrials.gov Identifier: NCT03592693). The current, randomized, placebo-controlled study will compare steroids/vitamin C versus placebo/placebo in septic shock, with respect to cerebral autoregulation, biomarkers, and functional… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Septic Shock
- What is being tested?
- Stress-dose Hydrocortisone plus Vitamin C
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 26 participants
- Where
- 1 siteGreece
- Study dates
- 6 Sep 2018to 16 Jan 2023
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of septic shock within 12 hours of admission to the intensive care unit (ICU).
Who cannot join
- Age < 18 years
- Pregnancy
- Patients with a fatal underlying disease who are unlikely to survive to hospital discharge
- Patients with acquired immunodeficiency and a CD4 count of < 50 / μL
- Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency.
- Patients with sepsis/septic shock transferred from another hospital
Show all 9Show fewer
- Patients with features of sepsis/septic shock > 12 hours
- Patients who require treatment with corticosteroids for an indication other than sepsis
- Patients with any history of an allergic reaction
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Combined Vitamin C, Stress-dose Steroids, and Thiamine on Cerebral Autoregulation and Functional Outcomes of Patients with Septic Shock
This study has been approved as a nested substudy of a multicenter trial (CORVICTES, Clinicaltrials.gov Identifier: NCT03592693). The current, randomized, placebo-controlled study will compare steroids/vitamin C versus placebo/placebo in septic shock, with respect to cerebral autoregulation, biomarkers, and functional outcome. The following hypotheses will be tested: The steroids/vitamin C/thiamine intervention may result in attenuation of the septic shock-associated impairment in cerebral autoregulation; and 2) The increased frequency of intact cerebral autoregulation in the intervention group may result in more neurologic failure free days and ventilator free days during a 60-day follow-up; improved survival to hospital discharge with good functional outcome; and better patient-reported health-related outcomes at 90-day follow-up.
Read the detailed description
BACKGROUND AND RATIONALE Septic Encephalopathy is a serious complication of sepsis / septic shock. In postmortem, human brain samples, two forms of neuraxonal injury have been described, namely, scattered ischemic lesions and diffuse injury. Prior evidence suggests that cerebral autoregulation is impaired in patients with septic shock, and this may render the central nervous system more vulnerable to direct ischemic damage, especially during episodes of hypotension. Near-infrared spectroscopy (NIRS) constitutes an established method of noninvasive assessment of cerebral autoregulation and provides the capability of semiquantitative assessment of regional cerebral blood flow.
In the context of a multicenter randomized clinical trial (RCT) evaluating the effect of steroids and antioxidants on the outcome of septic shock, we aim to assess cerebral autoregulation and frontal cortex perfusion using NIRS in patients who will be enrolled in the 25-bed intensive care unit (ICU) of Evaggelismos Hospital, Athens, Greece.
The rationale of the main study is based on the following facts: A large body of experimental data has demonstrated that both corticosteroids and intravenous vitamin C reduce activation of nuclear factor kappa beta (NFƘB), thereby attenuating the release of pro-inflammatory mediators. This may result in reduced endothelial permeability and improved macrocirculatory flow, and augmentation of the release of endogenous catecholamines and enhanced vasopressor responsiveness. Furthermore, a combined attenuation of the systemic inflammatory response, reduced vascular leakage, and improved macrocirculatory flow may partly contribute to the preservation of cerebral autoregulation and effective, regional brain perfusion. In addition, recent evidence suggests that thiamine may be neuroprotective in severe shock states.
Regarding the rationale and hypotheses of the current substudy: Recent, observational data suggest that impaired cerebral autoregulation is independently associated with 3-month mortality in patients with septic shock. Therefore, the current project aims to test the following hypotheses: 1) The steroids/vitamin C/thiamine intervention may result in attenuation of the septic shock-associated impairment in cerebral autoregulation; and 2) The increased frequency of intact cerebral autoregulation in the intervention group may result in more neurologic failure free days and ventilator free days during a 60-day follow-up; improved survival to hospital discharge with good functional outcome; and better patient-reported health-related outcomes at 90-day follow-up.
METHODS
NIRS monitoring will be applied for 60 min at 2 levels of mean arterial pressure (MAP; ie, 65-70 mmHg and 95-100 mmHg) within 24-30 hours, and within 48-54 hours and 72-78 hours after the diagnosis of the septic shock. Autoregulation will be assessed by using tissue oxygenation index values and concurrently recorded MAP values in a regression analysis and will be considered as adequate if the pertinent Pearson correlation coefficient is lower than 0.3. Cerebral blood flow will be assessed by determination of the blood flow index after bolus injection of 5 mg of indocyanine green.
Patients will be randomized to the intervention or control group in subgroups of 4 using the "Research Randomizer" software, version 4 (https://www.randomizer.org/). Substudy intervention: In concordance with the main study protocol as approved by the Institutional Review Board (IRB; ie, the Scientific Council) of Evaggelismos Hospital, Athens Greece, the substudy intervention will comprise the following:
Hydrocortisone: Hydrocortisone 50 mg initial/single bolus (5-mL syringe containing 50 mg of hydrocortisone in normal saline), followed by a 24-hour continuous infusion of 200 mg/day for 4 days. The daily hydrocortisone dose of 200 mg will be diluted in a 50 or 100 mL bag of normal saline.
Hydrocortisone placebo will be provided as an identical syringe/50 or 100 mL bag of normal saline.
Vitamin C: Vitamin C is provided by the manufacturer as a 50 mL vial at a concentration of 500mg/mL. Three (3) ml of the vitamin C solution will be diluted in a 50 or 100 mL bag of normal saline (1500 mg vitamin C in a 50 mL bag) which will then be infused over 1 hour. The bag will be labeled by the study's pharmacy team as "vitamin C". The dosing schedule is 1500 mg every 6 hours for 4 days or until discharge from the ICU.
Vitamin C placebo will consist of an identical bag of 50 or 100 mL normal saline (but with no vitamin C) and will be labeled vitamin C. Placebo will be infused over 60 min as per the infusion instructions of the active vitamin.
Thiamine: As a high percentage of septic patients have been shown to be thiamine-deficient, patients will receive intravenous thiamine 200 mg every 12 hours for 4 days or until ICU discharge. Thiamine is also a cofactor for the metabolism of oxalate (a byproduct of vitamin C metabolism), with thiamine deficiency increasing oxalate levels. To simplify the study protocol both the intervention and the control group will receive thiamine.
The study inclusion and exclusion criteria are detailed in the dedicated subsections.
DOCUMENTATION AND PATIENT FOLLOW-UP
Monitoring of patients over the first 10 days after randomization will include: 1) Determination and recording of hemodynamic parameters and hemodynamic support, blood gases and fluid balance over the previous 24 hours as well as arterial blood lactate and central venous oxygen saturation; 2) Blood sampling at 24, 48 and 72 hours and 7 days after randomization for determination of cytokines' concentrations; 3) Daily, routine laboratory investigations' results and prescribed treatment data; 4) the results of 4 daily (1 / 6 hours) blood glucose measurements will be recorded and the incidence of hyperglycemia (defined as blood glucose over 200 mg/dL) will be analyzed; 5) Daily calculation of the Sequential Organ Dysfunction Assessment Score; and 6) The source of the infection, the results of blood cultures and other biological specimen cultures, and the antibiograms.
The time to first cessation of vasopressor support will also be documented. Follow-up until day 60 postresuscitation will include organ failure-free days and ventilator-free days. Finally, the ICU length of stay, the hospital discharge date, and the morbidity and complications / adverse events during hospital stay will be recorded.
ICU management protocol:
All septic patients enrolled in this study will be managed by a standardized approach which will comprise:
- Empirical treatment with at least 2 broad spectrum antibiotics; antibiotic treatment will be deescalated according to microbiological data and clinical improvement
- A conservative strategy of fluid management
- A lung-protective ventilation strategy
- Limited use of sedative agents according to pertinent guidelines
- Enteral nutrition which will be started at 24 hours after ICU admission
- Prophylaxis against deep venous thrombosis prophylaxis with both enoxaparin (or heparin in patients with a calculated creatinine clearance < 30 mL/min) and sequential compression/decompression stockings
- Permissive hyperglycemia (ie, blood glucose of 150-200 mg/dL)
The study outcome measures are detailed in the dedicated subsection.
Sample size calculation: The previously reported frequency of impaired cerebral autoregulation is approximately 60% on day 2 after the diagnosis of sepsis/septic shock (3). The detection of a study intervention-related halving of the aforementioned proportion with an alpha value of 0.05 and a power of 0,80 would require the enrollment of 96 patients. As we estimate that at least 100 patients will be enrolled at Evagglismos hospital in the context of the steroids - vitamin C - thiamine multicenter RCT, we also propose a target enrollment of 100 patients for the current substudy.
G Power 3.1.9.2 Exact - Proportions: Inequality, two independent groups (Fisher's exact test) Options: Exact distribution Analysis: A priori: Compute required sample size Input: Tail(s) = Two Proportion p1 = 0.30 Proportion p2 = 0.60 α err prob = 0.05 Power (1-β err prob) = 0.80 Allocation ratio N2/N1 = 1 Output: Sample size group 1 = 48 Sample size group 2 = 48 Total sample size = 96 Actual power = 0.8004595 Actual α = 0.0290919
POSSIBLE SIGNIFICANCE OF STUDY RESULTS: In view of encouraging preliminary data on the corticosteroids / vitamin C, thiamine combination, we expect that the results of the current study will further elucidate important mechanisms underlying the (speculated) intervention-related benefit.
- Conditions
- Septic Shock
- Being tested
- Stress-dose Hydrocortisone plus Vitamin C, isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo
- Keywords
- Shock, Septic, Cerebrovascular Circulation, Spectroscopy, Near-Infrared, Patient Reported Outcome Measure
- Medical subject headings
- Shock, Septic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stress-dose Hydrocortisone plus Vitamin CDrug
Also called Vitamin-Steroid
Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placeboDrug
Also called Placebo-placebo
Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
| Study group | Role | What they receive |
|---|---|---|
| Steroids/Vitamin C group | Experimental | "Combined Vitamin C and Stress-Dose Hydrocortisone": Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization. Receives: Drug: Stress-dose Hydrocortisone plus Vitamin C |
| Control group | Placebo comparator | "Placebo plus placebo:" Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization. Receives: Drug: isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cerebral autoregulation
Cerebral autoregulation while increasing MAP from a minimum of 65-75 mmHg to a maximum of 90-100 mmHg by changing the vasopressor infusion rate.
Measured: 24-78 hours after randomization
Cerebral blood flow
Cerebral blood flow at an MAP of 65-75 mmHg and an MAP of 90-100 mmHg
Measured: 24-78 hours after randomization
Secondary outcomes (5)
Neurologic failure free days
Neurologic failure free days from day 1 to day 60 postrandomization; patients with a Glasgow Coma Scale Score of more than 9 will be considered as neurologic failure-free.
Measured: Days 1-60 after randomization
Ventilator-free days
Ventilator-free days from day 1 to day 60 postrandomization; on any given follow-up day, patients will be considered as ventilator-free only in the absence of any need for ventilatory support within the preceding 24 hours.
Measured: Days 1-60 after randomization
Favorable, Inhospital, Neurological Outcome
Survival to hospital discharge with a Cerebral Performance Category Score (CPC) of 1 or 2. The CPC score has 5 categories: 1 = good cerebral performance: the patient is conscious, alert, and able to work and lead a normal life; 2 = moderate cerebral disability: the patient is conscious and capable of independent activities of daily life; disorders such as hemiplegia, seizures, ataxia, cognitive changes, and/or noncerebral organ dysfunction causing moderate disability may be present; 3 = severe cerebral disability: patient is conscious and ambulatory but dependent on others, because of severe memory disturbance or dementia, or patient is paralyzed and can communicate only with his/her eyes, as in the locked-in syndrome; severe disability from noncerebral organ dysfunction may coexist; 4 = coma or vegetative state: patient is unconscious and unable of any verbal and/or psychological interaction with the environment; and 5 = death: certified brain death.
Measured: Days 1-60 after randomization
Patient-reported health-related quality of life: SF-36
Patient-reported health-related quality of life by using the Short Form-36 Quality of Life questionnaire; available from: https://repository.niddk.nih.gov/static/studies/halt-pkd/Forms/F038%20Quality%20of%20Life.pdf; https://www.optum.com/campaign/ls/outcomes-survey-request.html.
The Short Form 36 Quality of Life Questionnaire is a validated, 36-item, generic health status measure with scales of physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health, and reported health transition. The questionnaire is scored according to a norm-based scoring method. For example, assuming that an average normal person has a score of 50 in each scale, an individual respondent scoring below 45 is considered to have a "below-average" health status.
Measured: 90 days after randomization
Biomarkers
Plasma levels of tumor necrosis factor alpha (TNFa), interleukin (IL)-1 beta (1β), IL-6, IL-8, IL-10, Neuron Specific Enolase, and protein S100B at 24, 48, and 72 hours after randomization.
Measured: 24-72 hours after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2018
- Study start6 Sep 2018
- Primary completion16 Jan 2023
- Study completion16 Jan 2023
Why it stopped: Low rate of enrollment; publication of relevant results by other groups
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Septic ShockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Single-center, prospective, randomized, doubleblind, placebo-controlled, parallel-group clinical trial.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Athens
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Spyros D. Mentzelopoulos, University of Athens
- Investigators
- Spyros D Mentzelopoulos, MD, PhD, Principal investigator, University of Athens Medical SchoolAnastasia Kotanidou, MD, PhD, Principal investigator, University of Athens Medical SchoolStylianos Orfanos, MD, PhD, Study director, University of Athens Medical SchoolSpyros G Zakynthinos, MD. PhD, Study chair, University of Athens Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03649633
- Sponsor's protocol ID
- 163-10-5-2018
- Acronym
- CORVICTES-ΥΜ
- Status last verified
- Dec 2024
- First submitted
- 24 Aug 2018
- Last updated
- 19 Dec 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No specific plan
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Combined Vitamin C, Stress-dose Steroids, and Thiamine on Cerebral Autoregulation and Functional Outcomes of Patients with Septic Shock
- ClinicalTrials.gov ID
- NCT03649633
- Acronym / sponsor ID
- CORVICTES-ΥΜ / 163-10-5-2018
- Conditions
- Septic Shock
- Keywords
- Shock, Septic, Cerebrovascular Circulation, Spectroscopy, Near-Infrared, Patient Reported Outcome Measure
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Low rate of enrollment; publication of relevant results by other groups
- Enrolment
- 26 participants (actual)
- Lead sponsor
- University of AthensUniversity, hospital or other
- Study start
- 6 Sep 2018 (actual)
- Primary completion
- 16 Jan 2023 (actual)
- Study completion
- 16 Jan 2023 (actual)
- First posted
- 28 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study has been approved as a nested substudy of a multicenter trial (CORVICTES, Clinicaltrials.gov Identifier: NCT03592693). The current, randomized, placebo-controlled study will compare steroids/vitamin C versus placebo/placebo in septic shock, with respect to cerebral autoregulation, biomarkers, and functional outcome. The following hypotheses will be tested: The steroids/vitamin C/thiamine intervention may result in attenuation of the septic shock-associated impairment in cerebral autoregulation; and 2) The increased frequency of intact cerebral autoregulation in the intervention group may result in more neurologic failure free days and ventilator free days during a 60-day follow-up; improved survival to hospital discharge with good functional outcome; and better patient-reported health-related outcomes at 90-day follow-up.
Detailed description
BACKGROUND AND RATIONALE Septic Encephalopathy is a serious complication of sepsis / septic shock. In postmortem, human brain samples, two forms of neuraxonal injury have been described, namely, scattered ischemic lesions and diffuse injury. Prior evidence suggests that cerebral autoregulation is impaired in patients with septic shock, and this may render the central nervous system more vulnerable to direct ischemic damage, especially during episodes of hypotension. Near-infrared spectroscopy (NIRS) constitutes an established method of noninvasive assessment of cerebral autoregulation and provides the capability of semiquantitative assessment of regional cerebral blood flow.
In the context of a multicenter randomized clinical trial (RCT) evaluating the effect of steroids and antioxidants on the outcome of septic shock, we aim to assess cerebral autoregulation and frontal cortex perfusion using NIRS in patients who will be enrolled in the 25-bed intensive care unit (ICU) of Evaggelismos Hospital, Athens, Greece.
The rationale of the main study is based on the following facts: A large body of experimental data has demonstrated that both corticosteroids and intravenous vitamin C reduce activation of nuclear factor kappa beta (NFƘB), thereby attenuating the release of pro-inflammatory mediators. This may result in reduced endothelial permeability and improved macrocirculatory flow, and augmentation of the release of endogenous catecholamines and enhanced vasopressor responsiveness. Furthermore, a combined attenuation of the systemic inflammatory response, reduced vascular leakage, and improved macrocirculatory flow may partly contribute to the preservation of cerebral autoregulation and effective, regional brain perfusion. In addition, recent evidence suggests that thiamine may be neuroprotective in severe shock states.
Regarding the rationale and hypotheses of the current substudy: Recent, observational data suggest that impaired cerebral autoregulation is independently associated with 3-month mortality in patients with septic shock. Therefore, the current project aims to test the following hypotheses: 1) The steroids/vitamin C/thiamine intervention may result in attenuation of the septic shock-associated impairment in cerebral autoregulation; and 2) The increased frequency of intact cerebral autoregulation in the intervention group may result in more neurologic failure free days and ventilator free days during a 60-day follow-up; improved survival to hospital discharge with good functional outcome; and better patient-reported health-related outcomes at 90-day follow-up.
METHODS
NIRS monitoring will be applied for 60 min at 2 levels of mean arterial pressure (MAP; ie, 65-70 mmHg and 95-100 mmHg) within 24-30 hours, and within 48-54 hours and 72-78 hours after the diagnosis of the septic shock. Autoregulation will be assessed by using tissue oxygenation index values and concurrently recorded MAP values in a regression analysis and will be considered as adequate if the pertinent Pearson correlation coefficient is lower than 0.3. Cerebral blood flow will be assessed by determination of the blood flow index after bolus injection of 5 mg of indocyanine green.
Patients will be randomized to the intervention or control group in subgroups of 4 using the "Research Randomizer" software, version 4 (https://www.randomizer.org/). Substudy intervention: In concordance with the main study protocol as approved by the Institutional Review Board (IRB; ie, the Scientific Council) of Evaggelismos Hospital, Athens Greece, the substudy intervention will comprise the following:
Hydrocortisone: Hydrocortisone 50 mg initial/single bolus (5-mL syringe containing 50 mg of hydrocortisone in normal saline), followed by a 24-hour continuous infusion of 200 mg/day for 4 days. The daily hydrocortisone dose of 200 mg will be diluted in a 50 or 100 mL bag of normal saline.
Hydrocortisone placebo will be provided as an identical syringe/50 or 100 mL bag of normal saline.
Vitamin C: Vitamin C is provided by the manufacturer as a 50 mL vial at a concentration of 500mg/mL. Three (3) ml of the vitamin C solution will be diluted in a 50 or 100 mL bag of normal saline (1500 mg vitamin C in a 50 mL bag) which will then be infused over 1 hour. The bag will be labeled by the study's pharmacy team as "vitamin C". The dosing schedule is 1500 mg every 6 hours for 4 days or until discharge from the ICU.
Vitamin C placebo will consist of an identical bag of 50 or 100 mL normal saline (but with no vitamin C) and will be labeled vitamin C. Placebo will be infused over 60 min as per the infusion instructions of the active vitamin.
Thiamine: As a high percentage of septic patients have been shown to be thiamine-deficient, patients will receive intravenous thiamine 200 mg every 12 hours for 4 days or until ICU discharge. Thiamine is also a cofactor for the metabolism of oxalate (a byproduct of vitamin C metabolism), with thiamine deficiency increasing oxalate levels. To simplify the study protocol both the intervention and the control group will receive thiamine.
The study inclusion and exclusion criteria are detailed in the dedicated subsections.
DOCUMENTATION AND PATIENT FOLLOW-UP
Monitoring of patients over the first 10 days after randomization will include: 1) Determination and recording of hemodynamic parameters and hemodynamic support, blood gases and fluid balance over the previous 24 hours as well as arterial blood lactate and central venous oxygen saturation; 2) Blood sampling at 24, 48 and 72 hours and 7 days after randomization for determination of cytokines' concentrations; 3) Daily, routine laboratory investigations' results and prescribed treatment data; 4) the results of 4 daily (1 / 6 hours) blood glucose measurements will be recorded and the incidence of hyperglycemia (defined as blood glucose over 200 mg/dL) will be analyzed; 5) Daily calculation of the Sequential Organ Dysfunction Assessment Score; and 6) The source of the infection, the results of blood cultures and other biological specimen cultures, and the antibiograms.
The time to first cessation of vasopressor support will also be documented. Follow-up until day 60 postresuscitation will include organ failure-free days and ventilator-free days. Finally, the ICU length of stay, the hospital discharge date, and the morbidity and complications / adverse events during hospital stay will be recorded.
ICU management protocol:
All septic patients enrolled in this study will be managed by a standardized approach which will comprise:
- Empirical treatment with at least 2 broad spectrum antibiotics; antibiotic treatment will be deescalated according to microbiological data and clinical improvement
- A conservative strategy of fluid management
- A lung-protective ventilation strategy
- Limited use of sedative agents according to pertinent guidelines
- Enteral nutrition which will be started at 24 hours after ICU admission
- Prophylaxis against deep venous thrombosis prophylaxis with both enoxaparin (or heparin in patients with a calculated creatinine clearance < 30 mL/min) and sequential compression/decompression stockings
- Permissive hyperglycemia (ie, blood glucose of 150-200 mg/dL)
The study outcome measures are detailed in the dedicated subsection.
Sample size calculation: The previously reported frequency of impaired cerebral autoregulation is approximately 60% on day 2 after the diagnosis of sepsis/septic shock (3). The detection of a study intervention-related halving of the aforementioned proportion with an alpha value of 0.05 and a power of 0,80 would require the enrollment of 96 patients. As we estimate that at least 100 patients will be enrolled at Evagglismos hospital in the context of the steroids - vitamin C - thiamine multicenter RCT, we also propose a target enrollment of 100 patients for the current substudy.
G Power 3.1.9.2 Exact - Proportions: Inequality, two independent groups (Fisher's exact test) Options: Exact distribution Analysis: A priori: Compute required sample size Input: Tail(s) = Two Proportion p1 = 0.30 Proportion p2 = 0.60 α err prob = 0.05 Power (1-β err prob) = 0.80 Allocation ratio N2/N1 = 1 Output: Sample size group 1 = 48 Sample size group 2 = 48 Total sample size = 96 Actual power = 0.8004595 Actual α = 0.0290919
POSSIBLE SIGNIFICANCE OF STUDY RESULTS: In view of encouraging preliminary data on the corticosteroids / vitamin C, thiamine combination, we expect that the results of the current study will further elucidate important mechanisms underlying the (speculated) intervention-related benefit.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Single-center, prospective, randomized, doubleblind, placebo-controlled, parallel-group clinical trial.
| Arm | Type | Receives |
|---|---|---|
| Steroids/Vitamin C group | Experimental | Drug: Stress-dose Hydrocortisone plus Vitamin C"Combined Vitamin C and Stress-Dose Hydrocortisone": Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization. |
| Control group | Placebo comparator | Drug: isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo"Placebo plus placebo:" Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Diagnosis of septic shock within 12 hours of admission to the intensive care unit (ICU).
Key exclusion criteria (9 listed)
- Age < 18 years
- Pregnancy
- Patients with a fatal underlying disease who are unlikely to survive to hospital discharge
- Patients with acquired immunodeficiency and a CD4 count of < 50 / μL
- Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stress-dose Hydrocortisone plus Vitamin CAlso: Vitamin-SteroidTreatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness. | Drug | Steroids/Vitamin C group |
| isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placeboAlso: Placebo-placeboTreatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone). | Drug | Control group |
Primary outcome
Cerebral autoregulation
Time frame: 24-78 hours after randomization
Cerebral autoregulation while increasing MAP from a minimum of 65-75 mmHg to a maximum of 90-100 mmHg by changing the vasopressor infusion rate.
Cerebral blood flow
Time frame: 24-78 hours after randomization
Cerebral blood flow at an MAP of 65-75 mmHg and an MAP of 90-100 mmHg
5 secondary outcomes
Neurologic failure free days
Time frame: Days 1-60 after randomization
Ventilator-free days
Time frame: Days 1-60 after randomization
Favorable, Inhospital, Neurological Outcome
Time frame: Days 1-60 after randomization
Patient-reported health-related quality of life: SF-36
Time frame: 90 days after randomization
Biomarkers
Time frame: 24-72 hours after randomization
Results and safety
The study was stopped early (reason given: Low rate of enrollment; publication of relevant results by other groups). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2024.
- Individual participant dataSharing planned: No. No specific plan
Related trials for Septic Shock
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
ICU-SUCCEED for Survivors of Acute Respiratory Failure and Their Caregivers
Acute Respiratory Failure, Critical Illness
Not yet recruitingObservational study
Longitudinal Trajectories of Myocardial Work in Patients With Sepsis
Sepsis, Septic Shock Hyperdynamic
RecruitingObservational study
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Spyros D Mentzelopoulos, MD, PhD principal investigator
University of Athens Medical School
Anastasia Kotanidou, MD, PhD principal investigator
University of Athens Medical School
Stylianos Orfanos, MD, PhD study director
University of Athens Medical School
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Stress-dose Hydrocortisone plus Vitamin C in people with Septic Shock, run by University of Athens at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 19 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Low rate of enrollment; publication of relevant results by other groups). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cerebral autoregulation (time frame: 24-78 hours after randomization). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2024.